Leerink Partnrs Brokers Lower Earnings Estimates for MAZE
Research analysts at Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for shares of Maze Therapeutics in ...
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Leerink Partners
Leerink Partners upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) from a market perform rating to an outperform rating in a research report report published on Wednesday, MarketBeat ...
Fierce Pharma18h
FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk: reports
Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports.
Fierce Pharma18h
GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
10 Unstoppable Stocks That Could Double Your Money
Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors.
BioSpace18h
FDA Faces ‘Catastrophic Collapse’ as Massive Layoffs Endanger User Fee Program
The FDA derives just under half of its yearly funding from pharma user fees, which help support its operations and fund ...